

Fullerton Lux Funds – Asia Focus Equities - Class A (SGD)

May 2021


Investment Objective

The investment objective of the Fund is to achieve competitive risk adjusted returns on a relative basis.

Investment Focus and Approach

The Fund invests primarily in equities, index futures, cash and cash equivalents. Typically, the Fund will concentrate the investments in a limited number of holdings. The investment universe will include equities listed on exchanges in Asia, as well as equities of companies or institutions which have operations in, exposure to, or derive part of their revenue from Asia, wherever they may be listed. Indirect investments in equities may be via P-Notes where the underlying assets would comprise equities defined above. With effect from 17 July 2019, up to 35% of the Fund's NAV may be invested in China "A" Shares via the Stock Connects and/or any other means as may be permitted by the relevant regulations from time to time.

Performance (%)



	1 mth	3 mths	6 mths	1 yr	3 yrs	5 yrs	10 yrs	Sl. Ann. Ret.	Sl. Ann. Vol.
Fund (bid-to-bid)	1.40	-1.40	14.66	62.75	13.68	16.86	8.83	8.99	14.25
Fund (offer-to-bid)	-3.42	-6.09	9.20	55.00	11.86	15.73	8.31	8.51	NA
Benchmark	0.87	0.62	12.57	41.97	10.04	14.18	7.54	8.14	12.78

Returns of more than 1 year are annualised. Returns are calculated on a single pricing basis in SGD with net dividends and distributions (if any) reinvested. Offer-to-bid returns include an assumed preliminary charge of 5% which may or may not be charged to investors.

Benchmark: MSCI AC Asia ex Japan Net Index.

Source : Fullerton Fund Management Company Ltd, MSCI Inc. and Bloomberg.

Market Review

MSCI Asia ex Japan Index (in USD terms) had another strong month in May with the index up 3.7% which takes year to date performance to 6.5%. However, Asia continues to lag developed markets. India, China-A and Taiwan were the best performing markets while Thailand, Malaysia and Indonesia were the notable underperformers. By sector, Healthcare and Materials rallied the most while Consumer Discretionary and Communication Services were the laggards.

COVID resurgence which began in April, further intensified in May. Many countries like Taiwan and Singapore, which have till now managed to control the virus relatively well, also witnessed renewed outbreaks. Further, India and Malaysia continue to report record cases and fatalities. Economic data points for the month were relatively soft. China's May Manufacturing and non-manufacturing official PMIs were relatively stable MoM and remain firmly in expansion territory. However, a sharp rise in China's April PPI to 6.8% YoY has stoked inflation fears. PMI data for most other economies in Asia was also largely down sequentially with India's COVID ravaged economy reporting the largest drop in the region from 55.5 in April to 50.8 in May. Policy environment remains broadly supportive, however most central banks across Asia are coming to an end of the easing cycle and markets remain concerned about inflation and gradual withdrawal of stimulus measures.

Inception date

14 Jun 2010

Fund size

SGD 470.68 million

Base Currency

USD

Pricing Date

31 May 2021

NAV*

SGD 25.71

Management fee

Up to 1.75% p.a.

Preliminary Charge

Up to 5% of the subscription amount (equivalent to a maximum of 5.26315% of the Net Asset Value per Share)

Dealing day

Daily

Deadline

1pm (CET); 5pm (Singapore time) on each Business Day

Bloomberg Code

HCAASGA LX

ISIN Code

LU0516422366

The Fund is available for SRS subscription.

For additional information on Fullerton and its funds, please contact:

Fullerton Fund Management Company Ltd

3 Fraser Street
 #09-28 DUO Tower
 Singapore 189352

T +65 6808 4688

F +65 6820 6878

www.fullertonfund.com

UEN: 200312672W

* Figures have been truncated to 2 decimal places. The official price is published on Fullerton's website.

Investment Strategy

We maintain our constructive view on Asian Equities on the back of healthy earnings growth. Strong domestic consumption in China, favorable semi-conductor cycle as well as a recovery in hardest hit economies in South Asia towards 2H21 underpin the earnings recovery narrative for Asia.

Valuations have pulled back from recent highs but still remain more than 1 standard deviation above 5 and 10 year mean. Further, recent rise in bond yields imply that scope for valuations to re-rate from current levels is fairly limited. Thus, market upside is likely to come mainly from earnings growth which is still robust. Factset consensus estimates indicate a healthy 34% YoY earnings growth for MSCI Asia ex Japan for 2021.

Monetary tightening in China in the form of any premature withdrawal of liquidity support as well as COVID trajectory are main risks to Asian equities. In addition, Tensions between the US & China also remains a risk to Asia's supply-chain.

Geographical Breakdown

China	31.6%
Hong Kong	11.5%
India	7.5%
Korea	22.0%
Singapore	4.0%
Taiwan	17.0%
Cash and cash equivalents	6.5%

Sector Breakdown

Communication Services	16.0%
Consumer Discretionary	7.9%
Consumer Staples	1.5%
Energy	1.2%
Financials	12.8%
Health Care	5.5%
Industrial	9.1%
Information Technology	34.9%
Materials	4.4%
Cash and cash equivalents	6.5%

Top 5 Holdings

Taiwan Semiconductor Manufacturing	9.5%
Samsung Electronics	6.9%
Tencent Holdings	5.9%
AIA Group Limited	4.7%
Hyundai Motor Co Ltd	4.1%

Disclaimer: This publication is for information only and your specific investment objectives, financial situation and needs are not considered here. The value of units in the Fund and any accruing income from the units may fall or rise. Any past performance, prediction or forecast is not indicative of future or likely performance. Any past payout yields and payments are not indicative of future payout yields and payments. Distributions (if any) may be declared at the absolute discretion of Fullerton Fund Management Company Ltd (UEN: 200312672W) ("Fullerton") and are not guaranteed. Distribution may be declared out of income and/or capital of the Fund, in accordance with the prospectus. Where distributions (if any) are declared in accordance with the prospectus, this may result in an immediate reduction of the net asset value per unit in the Fund. Applications must be made on the application form accompanying the prospectus, which can be obtained from Fullerton or its approved distributors. You should read the prospectus and seek advice from a financial adviser before investing. If you choose not to seek advice, you should consider whether the Fund is suitable for you. The Fund may use or invest in financial derivative instruments. Please refer to the prospectus of the Fund for more information.

This advertisement or publication has not been reviewed by the Monetary Authority of Singapore.